Study Evaluating Efficacy and Safety of Crisaborole in Adults With Stasis Dermatitis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04091087|
Recruitment Status : Not yet recruiting
First Posted : September 16, 2019
Last Update Posted : September 16, 2019
|Condition or disease||Intervention/treatment||Phase|
|Stasis Dermatitis||Drug: crisaborole ointment Other: vehicle ointment||Phase 2|
Study C3291038 is a Phase 2a, randomized, double-blind, vehicle-controlled, parallel-group, proof of concept study to evaluate the efficacy, safety, and local tolerability of 6 weeks of treatment with crisaborole in adult participants with SD without active skin ulceration. Approximately 82 eligible participants will be randomized into the double blind treatment period in a 1:1 ratio to receive crisaborole ointment, 2% or vehicle twice daily for 6 weeks.
The study will recruit male and female participants aged ≥ 45 years with a clinical diagnosis of SD.
The total duration of participation in the study will be up to 14 weeks, including up to 4 weeks for screening, a 6 week double blind treatment period, and a follow-up period of 4 weeks after treatment completion.
Study enrollment and management will be de centralized, where participants do not visit an investigator or a clinic for clinical assessment. The participants will participate in the study at home. The sponsor (or designee) will provide home visits by qualified home visit practitioners (HVP), remote contact by telemedicine (or telephone), and clinical database electronic case report forms (eCRFs), eDiary, and other electronic data entries from 3rd party vendors for study data collection.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||82 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Local Tolerability of Crisaborole Ointment, 2%, in Adult Participants With Stasis Dermatitis Without Active Skin Ulceration|
|Estimated Study Start Date :||October 31, 2019|
|Estimated Primary Completion Date :||October 7, 2020|
|Estimated Study Completion Date :||October 7, 2020|
Experimental: crisaborole ointment
Drug: crisaborole ointment
Other Name: Eucrisa
Sham Comparator: vehicle ointment
Other: vehicle ointment
- Percent change from baseline in Total Sign Score [ Time Frame: 6 weeks ]Percent change from baseline in Total Sign Score at Week 6
- Investigator's Static Global Assessment [ Time Frame: Weeks 1-6 ]Proportion of participants with an Investigator's Static Global Assessment score of Clear (0) or Almost Clear (1) with at least a 2 grade improvement from baseline at all time points
- Total sign score [ Time Frame: Weeks 1-5 ]Percent change from baseline in total sign score at all time points except Week 6
- Investigator's Static Global Assessment [ Time Frame: Weeks 1-6 ]Proportion of participants with a ISGA score of Clear (0) or Almost Clear (1) at all time points
- Lesional percent body surface area [ Time Frame: Weeks 1-6 ]Percent change from baseline in lesional % Body Surface Area
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04091087
|Contact: Pfizer CT.gov Call Center||1-800-718-1021||ClinicalTrials.gov_Inquiries@pfizer.com|
|Study Director:||Pfizer CT.gov Call Center||Pfizer|